Clinical trials: Influenza, completed
Influenza
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated…
- Trial name
- NCT02369159
- Testing
- Peramivir, Oseltamivir
- Where
- 10 sites in United States, South Africa
- Volunteers
- 137 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Direct and Indirect Protection by Influenza Vaccine Given to Children in India
The study described here will immunize children with trivalent influenza vaccine (TIV) and determine whether this reduces influenza illness among the immunized children and their older family members.
- Trial name
- NCT00934245
- Testing
- Inactivated Trivalent Influenza Vaccine, Inactivated polio vaccine (IPV)
- Where
- India
- Volunteers
- 4,598 people, healthy volunteers welcome
- Sponsor
- Wayne Sullender, M.D.
Healthy
Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season
The purpose of this research study is to determine whether a functional fiber, galactooligosaccharide, can help maintain immune strength and digestive health in free-living older adults.
- Trial name
- GOS (NCT01302561)
- Testing
- Sucrose, Galactooligosaccharide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Emergencies, Flu
Burden of Influenza at Emergency Department Level : BIED
Seasonal influenza surveillance in France relies on several sources to detect the onset of the epidemic early, as well as to estimate the severity of epidemics and their impact on the health system.
- Trial name
- BIED (NCT04153331)
- Testing
- Nasal swab
- Where
- France
- Volunteers
- 2,487 people
- Sponsor
- Hospices Civils de Lyon
Healthy
A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults
Substudy A: The study aims to learn about the safety and effects of two new vaccines for RSV (RSVpreF) and influenza (modRNA qIRV) when given as a single shot compared to when given separately.
- Trial name
- NCT05788237
- Testing
- RSVpreF+qIRV, qIRV, RSVpreF
- Where
- Argentina
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
- Trial name
- NCT01827462
- Testing
- Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza, Human, Vaccination; Infection
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women
Comparative study of tolerability, reactogenicity, safety and immunogenicity Flu-M [Inactivated Split Influenza Vaccine] vs. the Ultrix® vaccine for the prevention of influenza in pregnant women in the 2nd-3rd trimesters of…
- Conditions
- Influenza, Human, Vaccination; Infection, Vaccines
- Trial name
- NCT05457894
- Testing
- Flu-M, Inactivated split influenza vaccine, Ultrix®, Inactivated Split Influenza Vaccine
- Where
- 5 sites in Russia
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.
- Trial name
- NCT00951041
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- 3 sites in Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics.
- Trial name
- NCT04590066
- Testing
- Flu shot text messages
- Where
- United States
- Volunteers
- 734,383 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Influenza, Acute Respiratory Infection
Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza
Vaccinating schoolchildren against influenza would prevent the disease among non-vaccinated household members.
- Trial name
- Xo_Gripe (NCT01693380)
- Testing
- Influenza vaccine, Control vaccine
- Where
- Brazil
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children
The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.
- Trial name
- NCT01323946
- Testing
- GSK Biologicals' investigational vaccine GSK1562902A
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.
- Trial name
- NCT02989194
- Testing
- VIS410 low dose, VIS410 high dose
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 150 people
- Sponsor
- Visterra, Inc.
Influenza
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
The purpose of this research study is to compare how the body reacts to different strengths of an experimental cell culture-grown whole virus A/H5N1 flu vaccine when given with or without the addition of aluminum hydroxide…
- Trial name
- NCT00382980
- Testing
- Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1
- Where
- 5 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Viral Infection
Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza
The primary object of this study is evaluating the efficacy of ZX-7101A tablets versus placebo in the treatment of uncomplicated simple influenza in adolescents.
- Trial name
- ZX-7101A-207 (NCT06099873)
- Testing
- ZX-7101A
- Where
- China
- Volunteers
- 361 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
The present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus monovalent…
- Trial name
- NCT00971100
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 3 sites in Belgium, Dominican Republic and 1 more
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
This randomized, partially-blinded, active comparator-controlled was conducted at multiple sites globally. The composition of QVLP used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins…
- Trial name
- NCT04622592
- Testing
- Instramuscular vaccine
- Where
- 14 sites in United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an…
- Trial name
- NCT05553301
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
To describe any degree of preference for the route of administration of Fluzone influenza vaccine, ID versus IM, in healthy adult subjects 18-49 years of age.
- Trial name
- NCT00623181
- Testing
- Fluzone: Influenza virus vaccine
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
The present study is intended to assess a novel formulation of FluLaval. The idea is to obtain preliminary data on the safety and immune response to the FluLaval TF influenza vaccine in adults.
- Trial name
- NCT00727428
- Testing
- FluLaval® TF
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.